Targeting adenosine for cancer immunotherapy

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

(2017) Bertrand Allard et al.   IMMUNOLOGICAL REVIEWS

Targeting A2 adenosine receptors in cancer

(2017) David Allard et al.   IMMUNOLOGY AND CELL BIOLOGY

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

(2017) Paul A. Beavis et al.   JOURNAL OF CLINICAL INVESTIGATION

Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).

(2017) Lawrence Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

(2017) Silvana Morello et al.   Journal of Translational Medicine

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease

(2017) Fabrizio Stocchi et al.   NEUROLOGY

CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer

(2017) Jieyao Li et al.   OncoImmunology

Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection

(2016) Xiao-Yan Cai et al.   MEDICINE

High expression of CD39 in gastric cancer reduces patient outcome following radical resection

(2016) Xiao-Yan Cai et al.   Oncology Letters

A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment

(2016) Akio Ohta   Frontiers in Immunology

CD73-adenosine reduces immune responses and survival in ovarian cancer patients

(2016) Pierre-Olivier Gaudreau et al.   OncoImmunology

Targeting CD73 in the tumor microenvironment with MEDI9447

(2016) Carl M. Hay et al.   OncoImmunology

Something in the Air: Hyperoxic Conditioning of the Tumor Microenvironment for Enhanced Immunotherapy

(2015) Robert D. Leone et al.   CANCER CELL

CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer

(2015) B. G. Leclerc et al.   CLINICAL CANCER RESEARCH

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer

(2015) Marian S. Wettstein et al.   DISEASE MARKERS

Loss of CD73-mediated actin polymerization promotes endometrial tumor progression

(2015) Jessica L. Bowser et al.   JOURNAL OF CLINICAL INVESTIGATION

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

(2015) G. K. Pennock et al.   ONCOLOGIST

Allosteric interactions between agonists and antagonists within the adenosine A2Areceptor-dopamine D2receptor heterotetramer

(2015) Jordi Bonaventura et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunological mechanisms of the antitumor effects of supplemental oxygenation

(2015) Stephen M. Hatfield et al.   Science Translational Medicine

CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression

(2015) Nathalie Bonnefoy et al.   OncoImmunology

Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment

(2014) C. Cekic et al.   CANCER RESEARCH

Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor

(2014) D. Mittal et al.   CANCER RESEARCH

Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)

(2014) S. M. Cushman et al.   CLINICAL CANCER RESEARCH

Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued

(2014) Annalisa Pinna   CNS DRUGS

Targeting Cancer-Derived Adenosine:New Therapeutic Approaches

(2014) A. Young et al.   Cancer Discovery

Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

(2014) J. Bastid et al.   Cancer Immunology Research

Hostile, Hypoxia-A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists

(2014) M. V. Sitkovsky et al.   Cancer Immunology Research

Extracellular adenosine regulates naive T cell development and peripheral maintenance

(2013) Caglar Cekic et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells

(2013) M. G. Terp et al.   JOURNAL OF IMMUNOLOGY

IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39

(2013) Ivan D Mascanfroni et al.   NATURE IMMUNOLOGY

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

(2013) S. Loi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors

(2013) Paul A. Beavis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma

(2013) Xiao-Xia Lu   WORLD JOURNAL OF GASTROENTEROLOGY

Increased CD39 expression on CD4+ T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia

(2012) Chava Perry et al.   ANNALS OF HEMATOLOGY

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

CD73-Deficient Mice Are Resistant to Carcinogenesis

(2012) J. Stagg et al.   CANCER RESEARCH

Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer inCd39/Entpd1null Mice

(2012) Xiaofeng Sun et al.   HEPATOLOGY

High expression of CD73 as a poor prognostic biomarker in human colorectal cancer

(2012) Xian-Rui Wu et al.   JOURNAL OF SURGICAL ONCOLOGY

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

(2011) Adam T. Waickman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis

(2011) J. Stagg et al.   CANCER RESEARCH

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

(2011) Long Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer

(2011) Beat M. Künzli et al.   Purinergic Signalling

CD73 Expression as a Potential Marker of Good Prognosis in Breast Carcinoma

(2011) Anna Supernat et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice

(2010) Xiaofeng Sun et al.   GASTROENTEROLOGY

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling

(2009) Carsten Linnemann et al.   IMMUNOLOGY

Human Follicular Lymphoma CD39+-Infiltrating T Cells Contribute to Adenosine-Mediated T Cell Hyporesponsiveness

(2009) S. P. Hilchey et al.   JOURNAL OF IMMUNOLOGY

Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial

(2009) H.H. Fernandez et al.   PARKINSONISM & RELATED DISORDERS

Adenosine receptors in regulation of dendritic cell differentiation and function

(2008) S. V. Novitskiy et al.   BLOOD